A battle over how to treat childhood obesity is brewing between those in favour and others who warn of the effects on growing bodies ...
3h
Hosted on MSNHims & Hers Super Bowl controversy: What the ad left out about its 'alternative' weight-loss drugsThe telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide ...
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...
Prescriptions of obesity management drugs have increased, and these increasing trends are associated with online search trends.
There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...
The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...
Big pharma’s pushing for PBS funding, and it’s kickstarting a shift to healthier snacks, smaller portions, and more ...
Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper savings to outdo his predecessor.
Telehealth provider Hims & Hers Health is defending its planned Super Bowl ad, which is styled as a political manifesto ...
Eggs are lean protein and appeal to people taking Ozempic, Wegovy, or other GLP-1 medications. But a big spike in prices has created a problem.
A new study from Mass Eye and Ear suggests that people taking semaglutide, a drug sold as Ozempic and Wegovy, may have a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results